Participated · Debt Financing · Aug 2026

Founded in 2014, inKind connects nearly five million guests with more than 7,700 restaurants across the U.S. The company provides restaurants with capital in exchange for food and beverage credits, which it sells to diners via its app while offering users up to 25% back in rewards. To date inKind has provided more than $600 million in funding to restaurants and has rewarded over four million users with more than $175 million in dining rewards. inKind positions its model as an alternative to expensive debt, dilutive equity, and discount-driven marketing for operators. Earlier this year the company raised $450 million to expand the platform to 10,000 additional restaurants and improve its in-app dining experience. The recent Liberty Mutual Investments financing is intended to further expand the restaurant network and support development of AI-native demand-generation tools.

Participated · Equity · Jul 2026

Sequotech is an IT group headquartered in the Jura region that offers specialized IT services and has pursued a buy-and-build strategy. Since Verium’s entry in 2020 the group has grown substantially and now reports more than CHF 85 million in revenue. Management and investors have moved the company into a Continuation Vehicle to support the next phase of development. Planned initiatives include further acquisitions, investment in organic growth, and strengthening group-wide competencies. The group is prioritizing expansion of its SME segment and scaling specialized services for large corporate clients. A new CEO was announced in November 2025 as part of the leadership transition accompanying this growth phase.

Participated · Series C · May 2025

Novisto is a Montreal-based sustainability data management and reporting software provider that helps companies collect, audit, and report ESG data. Its platform enables customers to collect, manage, approve, disclose, and defend sustainability data in one place efficiently and securely. The company serves global clients including Emirates Group, Bombardier, Moderna, Synopsys, and Deutsche Bank. Led by CEO Charles Assaf, Novisto intends to use the new funding to further enhance its sustainability platform and accelerate market leadership within Europe. Financially, the company has now raised over $55M to date, including the $27M Series C. Novisto builds ESG data-management software described as an "ERP for ESG," enabling companies to take a data-centric approach to sustainability reporting and risk management. The platform supports global customers including Asana, Manulife, and Sanofi. The company plans to use the new funding to scale product development, grow its customer base, and expand its team across the globe. Novisto was founded in 2019 and is led by Charles Assaf. It is headquartered in Montreal and has over 100 employees across North America and Europe. The recent Series B positions the company to accelerate its product and commercial growth. Novisto offers an end-to-end enterprise SaaS platform that centralizes and automates the collection, consolidation, and reporting of sustainability (ESG) data. The platform aims to help executives and ESG practitioners integrate sustainability into corporate strategy and link ESG performance to economic value creation. Novisto is an official Sustainability Accounting Standards Board (SASB) data licensee and a CDP Accredited Solutions Provider. Since launching at the end of 2019 it has gained traction with publicly listed customers including CAE, JetBlue, and TMX Group. In May 2021 Novisto raised US$8M in a Series A (bringing total funding to US$9.5M after a US$1.5M seed in 2020). The company plans to use the funding to triple its engineering and product teams, advance its product roadmap, and expand beyond North America into the European market.

Led · Debt Financing · Mar 2025

Nuvation Bio is focused on developing and commercializing oncology therapies, with taletrectinib as its lead asset. The company aims to fund U.S. commercialization of taletrectinib, if approved, and continue development of its clinical-stage pipeline. Management says the financings provide a path to potential profitability without the need for additional capital. Nuvation expects to be positioned to launch taletrectinib in mid-2025, subject to FDA approval. The transactions strengthen the company’s balance sheet and increase flexibility to pursue strategic opportunities. TD Cowen served as financial advisor and Cooley served as legal advisor to Nuvation Bio. Nuvation Bio is a stealth-mode biopharmaceutical company focused on developing next-generation therapies to address unmet needs in oncology. Its proprietary portfolio includes seven novel and mechanistically distinct oncology programs, each with multiple drug development candidates. The company intends to use new capital to expand its development activities and advance a number of its oncology programs. Nuvation’s executive team includes former senior leaders from Medivation alongside newly appointed senior scientists and clinical leaders. The company was founded in 2018 and operates out of New York City. Nuvation recently closed a major financing to fund its pipeline expansion.

Participated · Equity · Jun 2022

DiliTrust provides the DiliTrust Governance Suite, a unified, secure and user-friendly SaaS platform composed of modules for board management, legal entities, contracts, litigation and data rooms. The company serves more than 2,000 customers across nearly 50 countries and is a market leader in France, Canada, Italy, Spain and Morocco. DiliTrust reported turnover of nearly €20 million in 2021, employs more than 170 staff, and has sustained annual growth of over 30%. The product emphasizes security, traceability and ease of deployment to help in-house legal teams handle digital transformation, collaboration and compliance. DiliTrust plans to accelerate growth both organically and through acquisitions, pursue international expansion, continue product innovation and carry out a significant recruitment initiative over the next twelve months. DiliTrust offers a full range of SaaS-based corporate governance solutions and services for legal, financial and internal control functions, led by CEO Yves Garagnon. Its product suite includes DiliTrust Exec (board digitization), DiliTrust Governance (collaborative legal ops platform), DiliTrust Data Room (secure electronic datarooms) and DiliTrust MFT (secure large-file transfer). The company serves over 500 customers in more than 40 countries and maintains offices in Montreal, Toronto, Paris, Dubai and Milan. DiliTrust raised US$8m in new funding to support growth. Management intends to use the proceeds to open new markets, potentially through strategic acquisitions, to maintain technological leadership and to continue enhancing its product and service range. Calcium Capital made a minority investment alongside the current management team, which retains control of the capital.